A.P. Pharma Reapplies for FDA Approval (APPA)

Specialty pharmaceutical company A.P. Pharma (OTC: APPA) has just announced the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for APF530 which is the lead product candidate to be used in the prevention of chemotherapy-induced nausea and vomiting, or CINV. After resubmitting the NDA, the company is fairly certain that it will receive approval from the FDA in a few weeks’ time. However, the confirmation of acceptance and PDUFA, or Prescription Drug User Fee Act, goal date are just the first steps to gain complete FDA approval. After these steps are completed, the company hopes that the drug will be granted complete approval in approximately six months.

CINV and APF530

When it comes to treatment of cancer patients, the prevention and control of acute CINV is one of the top priorities of the medical world. Most patients who undergo chemotherapy experience some form of emesis or CINV if they are not given a drug to prevent and control the reaction before chemotherapy starts. This is where APF530 can help, as per A.P. Pharma.

This lead product developed by the company is being created to prevent and control acute and delayed onset of CINV. Other than the 5-HT3 antagonist, Granisetron, the product also contains one of A.P. Pharma’s most famous and proprietary delivery systems, the Biochronomer system. Due to the presence and usage of this delivery system, it is possible for the effects of the drug to remain constant over a period of five days after just one subcutaneous injection.

About A.P. Pharma

A.P. Pharma is an upcoming specialty pharmaceutical company that is developing a variety of products using its proprietary delivery system Biochronomer. This polymer-based drug delivery system is revolutionary because instead of needing one or more injections every single day, patients will be able to manage and function with one or two injections per week. Its latest product is APF530 and it is directed toward the prevention and control of acute onset and delayed onset CINV.

Market Movement

A.P. Pharma is a penny stock company that has become one of the most actively traded penny stocks in the over the counter markets. Opening share prices were noted at $0.6099 per share and the stock has climbed by 1.7%, or $0.01, to reach $0.61 on October 4, 2012.

Other penny stock companies that are on the most actively traded list are TagLikeMe (OTC: TAGG), which is a social media based tagging and sharing platform with the day’s trading volume at 68.7 million shares. Liberty Silver (OTC: LBSV) is a silver exploration and mining company whose penny stocks are among the most actively traded, coming in at nearly 1.7 million shares today. Along with A.P. Pharma, these penny stock companies are also trading in high volumes and are being bought and sold very actively in the OTC market.

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.

Published by Benjamin Roussey

Benjamin Roussey is from Sacramento, California. He has two master’s degrees and served four years in the U.S. Navy. His bachelor’s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master’s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http://www.facebook.com/ben.rouss

Recent Stories

SignUp Now For Our Featured Newsletter